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Background: Adjuvant endocrine therapy beyond 5 years reduces recurrence in patients with oestrogen receptor positive breast cancer. We have previously shown that immunohistochemical markers (IHC4) and two gene expression profile tests (Recurrence Score (RS)) and PAM50 Risk of Recurrence (ROR) are correlated with time to distant recurrence and have now assessed the value of each of these scores and routine clinical variables for predicting outcome, specifically in years 5-10.
Methods: We used univariate and multivariate proportional hazard models to determine the prognostic value of all variables and scores (IHC4, RS, ROR) for distant recurrence, separately in years 0-5 and specifically for years 5-10 for all patients.
Results: Nodal status and tumour size were at least as strong in years 5-10 as in years 0-5 (nodal status: χ2=21.72 vs. χ2=11.08; tumour size: χ2=10.52 vs. χ2=10.82). Ki67 and the overall IHC4 score were the only significant biomarkers related to distant recurrence univariately in the 5-10 year period (χ2=8.67, χ2=13.22, respectively). The ROR score was the strongest molecular prognostic factor in the late follow-up period (χ2=16.29), whereas IHC4 (χ2=7.41) and RS (χ2=5.55) were only weakly prognostic in this period. Similar results were seen for all subgroups and for all recurrences. 






Adjuvant chemotherapy and endocrine therapy for early breast cancer have had a considerable impact on outcomes  ADDIN EN.CITE [], but a substantial number of women, especially those with oestrogen receptor (ER) positive tumours, remain at risk for late recurrences. The annual rate is in excess of 2% for at least 15 years, even after 5 years of  tamoxifen therapy [] and currently it is not possible to identify a group of such women who can be considered as cured  ADDIN EN.CITE [, ]. This remains true for at least 10 years for women treated for 5 years with an aromatase inhibitor  ADDIN EN.CITE [].

Most of the studies of prevention of late relapse have been performed in women receiving tamoxifen as initial adjuvant endocrine therapy for early ER-positive breast cancer. The MA17 trial clearly showed that extended adjuvant therapy with letrozole following 5 years of tamoxifen prolongs disease-free survival and overall survival, regardless of patient’s nodal status involvement  ADDIN EN.CITE []. Brewster et al.  ADDIN EN.CITE [] found that oestrogen receptor positivity, nodal involvement, and grade were all associated with increased risk of late recurrence. It is of importance to determine to what extent the newer immunohistochemical and molecular scores can help in predicting late recurrence. 







The ATAC trial evaluated  the efficacy and safety of anastrozole versus tamoxifen given for 5 years in postmenopausal women with localised breast cancer []. The transATAC study collected formalin-fixed, paraffin embedded blocks from hormone-receptor positive breast cancers in a subset of women randomised to the monotherapy arms of the ATAC trial  ADDIN EN.CITE []. The current analysis includes all such patients from the United Kingdom, which have not receive chemotherapy and for whom the RS, the IHC4 and the ROR (PAM50 without tumour size) score was available (N=940). The laboratory methods to derive the RS, IHC4 and ROR score have been described in detail previously  ADDIN EN.CITE [, , ]. Briefly, the CTS contains information on nodal status, tumour size, grade, age, and treatment received and was developed on the transATAC dataset and has been described in detail previously  ADDIN EN.CITE []. The IHC4 score consists of a quantitative assessment of four variables (oestrogen receptor (ER), progesterone receptor (PgR), HER2, and ki67) and was also developed from the transATAC dataset in the presence of clinical variables  ADDIN EN.CITE []. For ROR, expression profiles for 50 classifier genes and eight housekeeping genes were measured using the nCounter platform (Nanostring Technologies). After normalization, the expression profile for each sample plus tumour size was used to calculate a predefined ROR score [].  In this analysis ROR is based on the ROR50 gene score without tumour size. The ATAC trial was performed in accordance with the Declaration of Helsinki (1996 revision), under the principles of good clinical practice and is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.










In a univariate analysis, tumour size and nodal status added the most prognostic information in years 0-5 (Table 1A). Figure 2A shows annual hazard rates for low risk women (node-negative, tumour size≤2cm) versus high risk women (node-positive, tumour size >2cm). The difference in distant recurrence rates continues for at least 8 years. Patients with high ER scores developed significantly fewer distant recurrences than those with lower scores and similar results were seen for the progesterone receptor (Table 1A). All IHC4 markers added significant prognostic information, with Ki67 being the strongest immunohistochemical marker in this time period (Table 1A). The CTS was the strongest score whereas IHC4 and ROR provided similar amount of information and RS was less prognostic (Table 1B). Figure 2B shows annual hazard rate curves for IHC4, RS, and ROR (cut-off point for all scores is the median). In univariate analyses, all scores had similar prognostic discrimination in years 0-5, and differences between scores are only seen in years 5-10 (Figure 2B). 

Multivariate analyses
The multivariate model included all variables that were significant in the univariate analysis (Table 1A). For the pre-defined scores, IHC4, RS and ROR were singly added to the CTS to create three multivariate models (Table 1B). Tumour size and nodal status were the strongest individual clinical factors in the multivariate analysis for years 0-5. Of the IHC markers, only PgR and Ki67 added clinically significant amounts of information in this period with similar effect sizes seen (Table 1A). When added to the CTS, the most prognostic information in years 0-5 was provided by IHC4, with the RS and ROR scores contributing similar prognostic information, when added to CTS (Table 1B).






In years 5-10, nodal status was the strongest prognostic factor of the individual clinical variables in the univariate analysis followed by tumour size. Grade did not add significant prognostic information in this time period (Table 1A). In years 5-10, ER, PgR and HER2 did not add any prognostic information, and Ki67 was the only significant immunohistochemical variable adding prognostic information in the univariate analysis in years 5-10 (χ2 =8.67) (Table 1A). 

CTS was the strongest prognostic factor in years 5-10 in the univariate analysis and provided very similar amount of prognostic information as for years 0-5 (Table 1B). ROR added less but substantial prognostic information in this time period, whereas IHC4 and RS added much less information (IHC4: χ2=13.22; Table 1B). The annual hazard rates curves for all three scores (split at the median) are shown in Figure 2B. The difference in annual hazard rates for women with a low score was greater for the ROR score than for either IHC4 or RS (Figure 2B). 

Multivariate analyses
Nodal status and tumour size were the only individual factors that added prognostic information in years 5-10 in the multivariate model (nodal status: χ2=21.72, tumour size: χ2=10.52). IHC4 (χ2=7.41) and RS (χ2=5.55) were weak prognostic factors in the 5-10 follow-up period (Table 1A). In contrast, ROR added a substantial amount of prognostic information in a model including CTS (χ2=16.29).

Table 2 shows results for distant recurrence in node-negative, node-positive, HER2-negative, HER2-negative/node-negative, and HER2-negative/node-positive populations only for the main four scores. For node-negative patients, IHC4 and RS did not add any prognostic information in this late time period (Table 2). In contrast, ROR added significant prognostic information in this time period in both the univariate and multivariate model. ROR was the only molecular score that added significant prognostic information in the late follow-up phase in the multivariate analysis in all five subgroups (Table 2). While all of the three molecular markers added significant information in years 5-10 (in contrast to years 0-5) in node-positive patients, IHC4 and RS lost their significance for years 5-10 in node-positive/HER2-negative patients in the multivariate analysis. Detailed results for clinical and immunohistochemical markers are shown in supplementary table 2.

The effect on outcomes of the difference in prognostic discrimination between the three molecular scores is shown in Figure 3 using Kaplan-Meier curves for IHC4, RS and ROR (split at the median) for each time period. It can be seen that the difference in distant recurrence rate between the low and high risk groups is approximately 7% for all three scores in years 0-5. However, in years 5-10 greater difference between low and high risk groups is seen for the ROR score (15.1%) compared to 5.4 % for RS and 9.8% for the IHC4 score.

Summary




The updated meta-analysis of individual patient data  by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) found that the risk of recurrence for ER-positive women after 5 years of tamoxifen is substantial in the adjuvant setting  ADDIN EN.CITE []. Furthermore, the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial showed that 10 years of tamoxifen use significantly reduced the risk of recurrence more than 5 years of tamoxifen treatment  ADDIN EN.CITE []. These results illustrate the need to address the importance of late recurrence in ER-positive breast cancer.

The transATAC cohort is a valuable resource for investigating factors that predict late recurrences as it is the only dataset for which data on IHC4, RS and ROR are available. Furthermore, this dataset is ideal to investigate the importance of late recurrence since all participants have had 5 years of either anastrozole or tamoxifen. We have previously shown that RS and IHC4 are independent predictors of distant recurrence in postmenopausal hormone receptor positive women  ADDIN EN.CITE [, ]. However it is well known that recurrence  risk extents for at least 20 years in these women [] and therefore it is crucial to identify markers that predict late recurrence. Here, we have investigated the relationship between clinical variables, immunohistochemical markers, and four different scores (CTS, IHC4, RS, ROR) in predicting distant recurrence in years 0-5 and 5-10 separately.

There are few reports on late recurrence of breast cancer more than 5 years after diagnosis  ADDIN EN.CITE [, ], and none of them have addressed immunohistochemical markers as prognostic factors, although there have been studies on mRNA expression profiles. Bianchini et al. [] reported on risk stratification by mitotic kinase (MKS) and a oestrogen-related score (ERS), and found that women with highly proliferative tumours and those with a high ESR score were at greater risk of late recurrence and may benefit from additional hormonal therapy. Sgroi et al. [] reported on the comparative performance of the Breast Cancer Index (BCI) versus IHC4 and RS for late recurrence and found that the BCI is a strong prognostic score in predicting late recurrence. Dubsky et al. [] reported on the EndoPredict test, which stratifies patients into low and high risk groups for late recurrence.

In our study we found that clinical variables to be strong prognostic factors in the initial 5 years of treatment, but only nodal status and tumour size remained prognostic in the multivariate analysis beyond 5 years of treatment. Although we have found that Ki67 has univariately prognostic value in years 5 to 10, it was not independent of classical variables in a multivariate analysis when all clinical factors were added to the model. None of the immunohistochemical markers added individually independent prognostic information for distant recurrence after 5 years of follow-up, although IHC4 returned some value. 

 The IHC4, RS and ROR scores added significant prognostic information in years 5-10 in the multivariate analyses, but of these the ROR was the strongest score in this late follow-up period. These results were seen for all 5 subgroups in this study. Although IHC4, RS and ROR added overall prognostic information in the late follow-up period, ROR discriminated best patients into low risk and high risk group for late distant recurrence. ROR has previously been shown to add prognostic information beyond that of standard markers  ADDIN EN.CITE [, ], but this is the first time this score has been compared to other scores for late recurrence in women with hormone receptor positive breast cancer. Although this analysis was based on the ROR50 gene score without tumour size, very similar results were found if the analysis was based on the ROR50 gene score with tumour size included.

Strengths of this analysis are the large sample size, a median long-term follow-up of 10 years, and use of an aromatase inhibitor or tamoxifen in all patients. Furthermore, clinical variables and immunohistochemical markers were available for all subjects as well as data on RS and ROR. Limitations include the fact that the comparison with IHC4 was conducted in the same study for which the score was derived, but sample splitting for each of the four scores (CTS, IHC4, RS, and ROR) was performed to remove any over-fitting. The transATAC cohort only includes participants from the United Kingdom, for which enough tissue was available to perform laboratory analyses for IHC4 and PAM50 ROR (N=940). Therefore, small tumours might be underrepresented in this cohort. The current study includes women for which all four scores and clinical variables were available, which constitutes 84% of the transATAC collection. Only 21% of all ATAC participants overall had chemotherapy for their initial treatment and only 18% with no initial chemotherapy treatment were included in the transATAC cohort where biopsy material was obtained. As a consequence we are unable to analyze the value of ROR in determining prognosis for patients receiving chemotherapy, or its ability to identify which patients might benefit from initial chemotherapy. This later question is best addressed in a trial where chemotherapy is a randomized treatment option.  
The prediction and treatment of late breast cancer recurrence is an important and largely unmet need, and remains a major clinical problem. While nodal status and tumour size added prognostic value 5 years after diagnosis, conventional immunohistochemical markers did not add information for late recurrence of those evaluated. The ROR score was the only molecular factor that showed promise in predicting late recurrence and to discriminate patients into low and high risk for late distant recurrence. These results help to indentify women who are at high risk of late recurrence and who may benefit from either more intensive treatment (i.e. chemotherapy) or extended endocrine treatment beyond 5 years. Validation of these results in other cohorts is needed.
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Table 1: Likelihood chi-square (χ2, P-value) for distant for all individual clinical variables (Table 1A) and all four scores (Table 1B). Both univariate and multivariate analysis are presented for years 0-5 and years 5-10 separately.

		0-5 years	5-10 years





































Table 2: Likelihood Chi-square (χ2, P-value) for distant recurrence for all scores according to subgroup. Both univariate and multivariate analyses are presented for years 0-5 and years 5-10 separately.



















































































Figure 1: Consolidated Standards of Reporting Trials flow diagram for study numbers. ATAC=Anastrozole, Tamozifen, Alone or in Combination, ER=Oestrogen Receptor, PgR=Progesterone Receptor, RS=Recurrence Score, IHC=Immunohistochemical markers, H&E=Hematoxylin & Eosin stain, RNA=Ribonucleid Acid, PAM50 ROR=Risk Of Recurrence.

Figure 2: Annual hazard rate curves (%) for distant recurrence according to risk group and scores (all split at the median). (IHC4=Immunohistochemical markers, RS=Recurrence Score, ROR=Risk of Recurrence)
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Supplemental table 1: Likelihood chi-square (χ2, P-value) for all recurrence for all individual clinical variables (Table 1A) and all four scores (Table 1B). Both univariate and multivariate analysis are presented for years 0-5 and years 5-10 separately.
		0-5 years(# of all recurrence = 83)		5-10 years(# of all recurrence = 107)
		Univariate	Multivariate		Univariate	Multivariate
Table 1A		χ2 (P-value)	χ2 (P-value)		χ2 (P-value)	χ2 (P-value)
	Nodal status(neg. vs. pos.)	17.24(<.001)	7.60(.006)		30.80(<.001)	18.99(<.001)






Likelihood ratio test based on Cox Proportional Hazard models for univariate and multivariate analyses. Changes in likelihood ratio values (χ2) were used. For multivariate model is in addition to model containing all other factors that were significant in the univariate model. All statistical tests were two-sided. ER=oestrogen receptor (continuous), PgR=progesterone receptor (continuous), Ki67 (continuous), HER2 (categorical). Nodal status, tumour size, and grade are all categorical variables.
		Univariate	Multivariate		Univariate	Multivariate









Supplemental Table 2: Likelihood chi-Square (χ2, P-value) for distant recurrence for all clinical and immunohistochemical variables according to subgroup. Both univariate and multivariate analyses are presented for years 0-5 and years 5-10 separately.










Nodal status (neg. vs. pos.)	-	-	-	-	-	-	-	-
Tumour size (≤2cm vs. >2cm)	11.85(<.001)	6.76(.009)	8.70(.003)	-	5.84(.02)	4.16(.04)	3.11(.08)	-






Nodal status (neg. vs. pos.)	29.30(<.001)	17.87(<.001)	21.66(<.001)	13.13(<.001)				
Tumour size (≤2cm vs. >2cm)	21.98(<.001)	9.03(.003)	20.72(<.001)	11.48(<.001)				






Nodal status (neg. vs. pos.)	-	-	-	-	-	-	-	-
Tumour size (≤2cm vs. >2cm)	7.34(.007)	5.32(.02)	11.93(<.001)	10.15(.001)	4.73(.03)	4.53(.04)	2.10(.1)	-





* Likelihood ratio test based on Cox Proportional Hazard models for univariate and multivariate analyses. Changes in likelihood ratio values (χ2) were used. For multivariate analysis, the model is in addition to model containing all other factors that were significant in the univariate model. All statistical tests were two-sided. ER=oestrogen receptor (continuous), PgR=progesterone receptor (continuous), Ki67 (continuous), HER2 (categorical). Nodal status, tumour size, and grade are all categorical variables.
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